The online version of this article (https://doi.org/10.1186/s12885-018-4437-z) contains supplementary material, which is available to authorized users.
Metabolomics is emerging as an important tool for detecting differences between diseased and non-diseased individuals. However, prospective studies are limited.
We examined the detectability, reliability, and distribution of metabolites measured in pre-diagnostic plasma samples in a pilot study of women enrolled in the Northern California site of the Breast Cancer Family Registry. The study included 45 cases diagnosed with breast cancer at least one year after the blood draw, and 45 controls. Controls were matched on age (within 5 years), family status, BRCA status, and menopausal status. Duplicate samples were included for reliability assessment. We used a liquid chromatography/gas chromatography mass spectrometer platform to measure metabolites. We calculated intraclass correlations (ICCs) among duplicate samples, and coefficients of variation (CVs) across metabolites.
Of the 661 named metabolites detected, 338 (51%) were found in all samples, and 490 (74%) in more than 80% of samples. The median ICC between duplicates was 0.96 (25th – 75th percentile: 0.82–0.99). We observed a greater than 20% case-control difference in 24 metabolites (p < 0.05), although these associations were not significant after adjusting for multiple comparisons.
These data show that assays are reproducible for many metabolites, there is a minimal laboratory variation for the same sample, and a large between-person variation. Despite small sample size, differences between cases and controls in some metabolites suggest that a well-powered large-scale study is likely to detect biological meaningful differences to provide a better understanding of breast cancer etiology.
Additional file 1: TableS1. Number of metabolites measured in plasma of BCFR participants (DOCX 17 kb)12885_2018_4437_MOESM1_ESM.docx
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong Y-N, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive Cancer network. Cancer. 2012;118(22):5463–72. CrossRefPubMedPubMedCentral
Mondul AM, Moore SC, Weinstein SJ, Männistö S, Sampson JN, Albanes D. 1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics : Official journal of the Metabolomic Society. 2014;10(5):1036–41. CrossRef
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910–14.
Budczies J, Brockmoller SF, Muller BM, Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, Griffin JL, Oresic M, Dietel M, Denkert C, et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteome. 2013;94:279–88. CrossRef
Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, Ricks-Santi LJ, Dasi S, Day A, Blackman KW, Frederick W, et al. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics Proteomics. 2014;11(6):279–94. PubMed
Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W, Sawyer MB. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16(23):5835–41. CrossRef
John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, et al. The breast Cancer family registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6(4):R375–89. CrossRefPubMedPubMedCentral
Terry MB, Phillips KA, Daly MB, John EM, Andrulis IL, Buys SS, Goldgar DE, Knight JA, Whittemore AS, Chung WK, et al. Cohort profile: the breast Cancer prospective family study cohort (ProF-SC). Int J Epidemiol. 2016;45(3):683–92.
Smith CAB. On the estimation of intraclass correlation. Ann Hum Genet. 1956;21:363–73. CrossRef
Wolack M: ICC: facilitating estimation of the intraclass correlation coefficient. 2015 Available at: https://cranr-projectorg/web/packages/ICC/ICCpdf Accessed 8 Sep 2016 .
Kim J-O MC. In: Uslaner EM, editor. FACTOR ANALYSIS statistical methods and practical issues. Iowa City, IA: Sara Miller McCune; 1978.
Sampson JN, Boca SM, Shu XO, Stolzenberg-Solomon RZ, Matthews CE, Hsing AW, Tan YT, Ji BT, Chow WH, Cai Q, et al. Metabolomics in epidemiology: sources of variability in metabolite measurements and implications. Cancer Epidemiol Biomark Prev. 2013;22(4):631–40. CrossRef
- Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry
Marcelle M. Dougan
Lisa W. Chu
Robert W. Haile
Alice S. Whittemore
Summer S. Han
Steven C. Moore
Joshua N. Sampson
Irene L. Andrulis
Esther M. John
Ann W. Hsing
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II